Arya R, Kumar S, Vinetz J, Kim J, Chaurasia R
Expert Rev Mol Med. 2024; 26:e32.
PMID: 39639643
PMC: 11629464.
DOI: 10.1017/erm.2024.29.
Nie Q, Sun D, Zhu M, Tu S, Chen N, Chen H
BMC Infect Dis. 2023; 23(1):832.
PMID: 38012619
PMC: 10680243.
DOI: 10.1186/s12879-023-08509-0.
Munoz-Egea M, Akir A, Esteban J
Biofilm. 2023; 5:100107.
PMID: 36798742
PMC: 9925856.
DOI: 10.1016/j.bioflm.2023.100107.
Karuniawati A, Burhan E, Koendhori E, Sari D, Haryanto B, Nuryastuti T
Front Med (Lausanne). 2023; 9:909198.
PMID: 36743681
PMC: 9896521.
DOI: 10.3389/fmed.2022.909198.
Sinshaw W, Kebede A, Bitew A, Tadesse M, Mehamed Z, Alemu A
Afr J Lab Med. 2022; 11(1):1671.
PMID: 36091348
PMC: 9453192.
DOI: 10.4102/ajlm.v11i1.1671.
Cost-effectiveness of GeneXpert Omni compared with GeneXpert MTB/Rif for point-of-care diagnosis of tuberculosis in a low-resource, high-burden setting in Eastern Uganda: a cost-effectiveness analysis based on decision analytical modelling.
Ejalu D, Irioko A, Kirabo R, Mukose A, Ekirapa E, Kagaayi J
BMJ Open. 2022; 12(8):e059823.
PMID: 35998960
PMC: 9403108.
DOI: 10.1136/bmjopen-2021-059823.
Need for caution when interpreting Xpert MTB/RIF results for rifampin resistance among children.
Murithi W, Click E, McCarthy K, Okeyo E, Sitati R, Anyango I
Int J Tuberc Lung Dis. 2021; 25(11):911-916.
PMID: 34686233
PMC: 11587784.
DOI: 10.5588/ijtld.21.0126.
Rifampicin resistance in in Iran: a two-centre study.
Bahraminia F, Zangiabadian M, Nasiri M, Fattahi M, Goudarzi M, Ranjbar R
New Microbes New Infect. 2021; 42:100909.
PMID: 34336229
PMC: 8313744.
DOI: 10.1016/j.nmni.2021.100909.
Bronchial brushing Xpert improves the diagnostic efficiency of sputum Xpert in patients with pulmonary tuberculosis.
He Y, Wu Y, Han C, Gong H, Wang M
Ther Adv Infect Dis. 2021; 8:20499361211020174.
PMID: 34164125
PMC: 8188970.
DOI: 10.1177/20499361211020174.
Discordant line probe genotypic testing vs culture-based drug susceptibility phenotypic testing in TB endemic KwaZulu-Natal: Impact on bedside clinical decision making.
Mahomed S, Mlisana K, Cele L, Naidoo K
J Clin Tuberc Other Mycobact Dis. 2020; 20:100176.
PMID: 32793816
PMC: 7414011.
DOI: 10.1016/j.jctube.2020.100176.
The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.
Shibabaw A, Gelaw B, Gebreyes W, Robinson R, Wang S, Tessema B
PLoS One. 2020; 15(2):e0229040.
PMID: 32053661
PMC: 7018133.
DOI: 10.1371/journal.pone.0229040.
Diagnosis of active tuberculosis disease: From microscopy to molecular techniques.
Caulfield A, Wengenack N
J Clin Tuberc Other Mycobact Dis. 2019; 4:33-43.
PMID: 31723686
PMC: 6850262.
DOI: 10.1016/j.jctube.2016.05.005.
Xpert MTB/RIF performance to diagnose tuberculosis and rifampicin resistance in a reference centre in southern Brazil.
Feliciano C, Menon L, Anselmo L, Dippenaar A, Warren R, Silva Jr W
ERJ Open Res. 2019; 5(3).
PMID: 31404338
PMC: 6680070.
DOI: 10.1183/23120541.00043-2019.
Xpert MTB/RIF assay for the diagnosis of rifampicin resistance in different regions: a meta-analysis.
Zong K, Luo C, Zhou H, Jiang Y, Li S
BMC Microbiol. 2019; 19(1):177.
PMID: 31382894
PMC: 6683411.
DOI: 10.1186/s12866-019-1516-5.
Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.
Horne D, Kohli M, Zifodya J, Schiller I, Dendukuri N, Tollefson D
Cochrane Database Syst Rev. 2019; 6:CD009593.
PMID: 31173647
PMC: 6555588.
DOI: 10.1002/14651858.CD009593.pub4.
Diagnosis of rifampicin-resistant tuberculosis: Discordant results by diagnostic methods.
Mwanza W, Milimo D, Chilufya M, Kasese N, Lengwe M, Munkondya S
Afr J Lab Med. 2018; 7(2):806.
PMID: 30568904
PMC: 6295983.
DOI: 10.4102/ajlm.v7i2.806.
Magnetic Nanoparticle-Based Biosensing Assay Quantitatively Enhances Acid-Fast Bacilli Count in Paucibacillary Pulmonary Tuberculosis.
Gordillo-Marroquin C, Gomez-Velasco A, Sanchez-Perez H, Pryg K, Shinners J, Murray N
Biosensors (Basel). 2018; 8(4).
PMID: 30545099
PMC: 6315978.
DOI: 10.3390/bios8040128.
Added Value of Xpert MTB/RIF Ultra for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting.
Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K
J Clin Microbiol. 2018; 57(2).
PMID: 30541937
PMC: 6355522.
DOI: 10.1128/JCM.01717-18.
Unsuccessful Xpert MTB/RIF results: the Nigerian experience.
Gidado M, Nwokoye N, Nwadike P, Ajiboye P, Eneogu R, Useni S
Public Health Action. 2018; 8(1):2-6.
PMID: 29581936
PMC: 5858060.
DOI: 10.5588/pha.17.0080.
Performance of the Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis and rifampin resistance in a low-incidence, high-resource setting.
Rice J, Seifert M, Moser K, Rodwell T
PLoS One. 2017; 12(10):e0186139.
PMID: 29016684
PMC: 5633176.
DOI: 10.1371/journal.pone.0186139.